pour la recherche uniquement
Réf. CatalogueS1135
| Cibles apparentées | Bcl-2 Caspase PD-1/PD-L1 Ferroptosis p53 Apoptosis related Synthetic Lethality STAT TNF-alpha Ras |
|---|---|
| Autre Antifolate Inhibiteurs | L-5-Methyltetrahydrofolate calcium Calcium N5-methyltetrahydrofolate |
| Lignées cellulaires | Type dessai | Concentration | Temps dincubation | Formulation | Description de lactivité | PMID |
|---|---|---|---|---|---|---|
| PANC-1 | Function Assay | 84 μM | 24 h | enhances EGFR, HER3 and AKT phosphorylation levels | 22977607 | |
| BXPC-3 | Function Assay | 39.86 μM | 24 h | enhances EGFR, HER3 and AKT phosphorylation levels | 22977607 | |
| PANC-1 | Function Assay | 84 μM | 24 h | enhances EGFR phosphorylated levels, and the protein levels | 22977607 | |
| BXPC-3 | Function Assay | 39.86 μM | 24 h | enhances EGFR phosphorylated levels, and the protein levels | 22977607 | |
| BXPC-3 | Function Assay | 39.86 μM | 24 h | induces S arrest (P<0.05) and decreases the number of cells in the G2/M phase | 22977607 | |
| PANC-1 | Growth Inhibition Assay | IC50=83.76±0.19 μM | 22977607 | |||
| BXPC-3 | Growth Inhibition Assay | IC50=39.86±1.68 μM | 22977607 | |||
| Jurkat | Growth Inhibition Assay | 48 h | proportion of live cells=76.7±4.3 % | 23840376 | ||
| DM-3 | Growth Inhibition Assay | 48 h | proportion of live cells=101.3±2.8 % | 23840376 | ||
| JL-1 | Growth Inhibition Assay | 48 h | proportion of live cells=98.2±2.2 % | 23840376 | ||
| ZL-34 | Growth Inhibition Assay | 48 h | proportion of live cells=95.7±6.5 % | 23840376 | ||
| STAV-FCS | Growth Inhibition Assay | 48 h | proportion of live cells=88.1±8.9 % | 23840376 | ||
| M-14-K | Growth Inhibition Assay | 48 h | proportion of live cells=81.8±12.9 % | 23840376 | ||
| STAV-AB | Growth Inhibition Assay | 48 h | proportion of live cells=64.4±21.8 % | 23840376 | ||
| LoVo | Function Assay | 0.05 μM | 72 h | DMSO | increases the percentage of cells in the S phase | 23959460 |
| HT-29 | Function Assay | 0.05 μM | 72 h | DMSO | increases the percentage of cells in the S phase | 23959460 |
| WiDr | Growth Inhibition Assay | 72 h | DMSO | IC50=0.019 ± 0.002 μM | 23959460 | |
| SW1116 | Growth Inhibition Assay | 72 h | DMSO | IC50=1.70 ± 0.03 μM | 23959460 | |
| HCT116 | Growth Inhibition Assay | 72 h | DMSO | IC50=0.049 ± 0.013 μM | 23959460 | |
| SW620 | Growth Inhibition Assay | 72 h | DMSO | IC50=1.09 ± 0.01 μM | 23959460 | |
| LoVo | Growth Inhibition Assay | 72 h | DMSO | IC50=0.032 ± 0.002 μM | 23959460 | |
| HT-29 | Growth Inhibition Assay | 72 h | DMSO | IC50=10.07 ± 0.94 μM | 23959460 | |
| A549/PEM-16 | Growth Inhibition Assay | 96 h | IC50=51.45 μM | 24348854 | ||
| A549/PEM-6.4 | Growth Inhibition Assay | 96 h | IC50=23.39 μM | 24348854 | ||
| A549/PEM-1.6 | Growth Inhibition Assay | 96 h | IC50=5.03 μM | 24348854 | ||
| A549 | Growth Inhibition Assay | 96 h | IC50=1.35 μM | 24348854 | ||
| MSTO-211H | Cell Viability Assay | 1-10 μg/ml | 72 h | IC50~0.04 μg/ml | 24378576 | |
| Y-meso14 | Cell Viability Assay | 1-10 μg/ml | 72 h | IC50>10 μg/ml | 24378576 | |
| H290 | Cell Viability Assay | 1-10 μg/ml | 72 h | IC50>10 μg/ml | 24378576 | |
| H226 | Cell Viability Assay | 1-10 μg/ml | 72 h | IC50>10 μg/ml | 24378576 | |
| H1299 | Growth Inhibition Assay | IC50=1.84 μM | 24418519 | |||
| H1993 | Growth Inhibition Assay | IC50=0.17 μM | 24418519 | |||
| A549 | Function Assay | 0.1/0.3/0.5/1 μM | 24/48 h | DMSO | produces the formation of AVOs in a dose-dependent manner | 24626722 |
| A549 | Cell Viability Assay | 0.1/0.3/0.5/1 μM | 24/48 h | DMSO | inhibits cell viability dose and time dependently | 24626722 |
| MES04 | Growth Inhibition Assay | IC50>100 μM | 24714722 | |||
| MES01 | Growth Inhibition Assay | IC50>100 μM | 24714722 | |||
| H2452 | Growth Inhibition Assay | IC50>100 μM | 24714722 | |||
| H2052 | Growth Inhibition Assay | IC50=0.57±0.34 μM | 24714722 | |||
| 211H | Growth Inhibition Assay | IC50=0.07±0.01 μM | 24714722 | |||
| H28 | Growth Inhibition Assay | IC50=0.07±0.02 μM | 24714722 | |||
| PC9/GR | Function Assay | 4.94 μM | 72 h | increases p-AKT levels | 24840891 | |
| PC9/GR | Function Assay | 4.94 μM | 72 h | increases p-ERK levels | 24840891 | |
| PC9/GR | Apoptosis Assay | 4.94 μM | 72 h | induces 19.54﹪ apoptosis | 24840891 | |
| PC9 | Apoptosis Assay | 16 nM | 72 h | induces 14.54﹪ apoptosis | 24840891 | |
| PC9/GR | Function Assay | 4.94 μM | 72 h | induces S-phase arrest | 24840891 | |
| PC9 | Function Assay | 16 nM | 72 h | induces S-phase arrest | 24840891 | |
| PC9/GR | Growth Inhibition Assay | 72 h | IC50=4.94±0.440 μM | 24840891 | ||
| PC9 | Growth Inhibition Assay | 72 h | IC50=16.05±1.85 nM | 24840891 | ||
| A549 | Function Assay | 0.1/0.3/1 μM | 48 h | increases the ratio of S-phase population | 24847863 | |
| A549 | Apoptosis Assay | 0.1/0.3/1 μM | 48 h | induces apoptosis in a dose dependent manner | 24847863 | |
| A549 | Function Assay | 0.1/0.3/1 μM | 48 h | increases the level of phosphorylated Akt in a dose dependent manner | 24847863 | |
| A549 | Function Assay | 1 µM | 4/8/12/24/48 h | increases the level of phosphorylated Akt in a time dependent manner | 24847863 | |
| A549 | Function Assay | 5 μM | 8 h | increases Mcl-1 ubiquitination levels | 24991768 | |
| A549 | Apoptosis Assay | 2.5 μM | 48 h | induces apoptosis | 24991768 | |
| H1792 | Function Assay | 2.5/5/10 μM | 48 h | downregulates Mcl-1 | 24991768 | |
| A549 | Function Assay | 2.5/5/10 μM | 48 h | downregulates Mcl-1 | 24991768 | |
| H1792 | Function Assay | 2.5 μM | 48 h | induces caspase-9, caspase-3 and poly (ADP-ribose) polymerase (PARP) cleavage | 24991768 | |
| A549 | Function Assay | 2.5 μM | 48 h | induces caspase-9, caspase-3 and poly (ADP-ribose) polymerase (PARP) cleavage | 24991768 | |
| H1792 | Function Assay | 2.5/5/10 μM | 48 h | increases Noxa expression significantly | 24991768 | |
| A549 | Function Assay | 2.5/5/10 μM | 48 h | increases Noxa expression significantly | 24991768 | |
| A549 | Function Assay | 1 μM | 48 h | leads to mitochondrial dysfunction combined with simvastatin | 25096993 | |
| MSTO-211 | Function Assay | 1 μM | 48 h | leads to mitochondrial dysfunction combined with simvastatin | 25096993 | |
| A549 | Function Assay | 1 μM | 48 h | enhances intracellular ROS production combined with simvastatin | 25096993 | |
| MSTO-211 | Function Assay | 1 μM | 48 h | enhances intracellular ROS production combined with simvastatin | 25096993 | |
| A549 | Apoptosis Assay | 1 μM | 48 h | enhances caspase-dependent apoptosis combined with simvastatin | 25096993 | |
| MSTO-211 | Apoptosis Assay | 1 μM | 48 h | enhances caspase-dependent apoptosis combined with simvastatin | 25096993 | |
| A549 | Cell Viability Assay | 1 μM | 48 h | produces a synergistic inhibitory effect on the cell growth combined with simvastatin | 25096993 | |
| MSTO-211 | Cell Viability Assay | 1 μM | 48 h | produces a synergistic inhibitory effect on the cell growth combined with simvastatin | 25096993 | |
| H1299 | Cell Viability Assay | 1-1000 nM | 72 h | IC50=178 nM | 25145669 | |
| A549 | Cell Viability Assay | 1-1000 nM | 72 h | IC50=137 nM | 25145669 | |
| MG-63 | Cell Viability Assay | 0.01-100 μM | 72 h | inhibits cell viability dosedependently | 25152399 | |
| U20S | Cell Viability Assay | 0.01-100 μM | 72 h | inhibits cell viability dosedependently | 25152399 | |
| HepG3 | Function Assay | 10 μM | 48 h | upregulates phosphorylated (p-) MEK1/2 (Ser217/221) and p-ERK1/2 (Thr202/Tyr204) | 25446102 | |
| HepG3 | Function Assay | 0.1–100 μM | 48 h | activates cyto-protective autophagy | 25446102 | |
| HepG3 | Function Assay | 0.1–100 μM | 48 h | induces p62 downregulation as well as Beclin-1 and LC3B-II upregulation | 25446102 | |
| HepG2 | Apoptosis Assay | 0.1–100 μM | 72 h | induces apoptosis slightly at high concerntration | 25446102 | |
| HepG2 | Cell Viability Assay | 0.1–100 μM | 72 h | high concentrations of pemetrexed at (10/100 μM) only slightly inhibits HepG2 cell survival | 25446102 | |
| A459 | Apoptosis Assay | 4μM | 48 h | induces apoptosis | 25743822 | |
| A459 | Function Assay | 1/2/4 μM | 48 h | decreases the levels of p-Akt | 25743822 | |
| A459 | Function Assay | 1/2/4 μM | 24/48 h | induces G1 phase arrest in dose- and time dependent manner | 25743822 | |
| T47D | Growth Inhibition Assay | 0.234 mM | 72 h | growth inhibition=30﹪ | 25975637 | |
| HeLa | Growth Inhibition Assay | 0.234 mM | 72 h | growth inhibition=20﹪ | 25975637 | |
| A549 | Growth Inhibition Assay | 0.234 mM | 72 h | growth inhibition=50﹪ | 25975637 | |
| Vero | Growth Inhibition Assay | 0.234 mM | 72 h | growth inhibition=20﹪ | 25975637 | |
| T47D | Growth Inhibition Assay | 0.234 mM | 48 h | growth inhibition=20﹪ | 25975637 | |
| HeLa | Growth Inhibition Assay | 0.234 mM | 48 h | growth inhibition=10﹪ | 25975637 | |
| A549 | Growth Inhibition Assay | 0.234 mM | 48 h | growth inhibition=30﹪ | 25975637 | |
| Vero | Growth Inhibition Assay | 0.234 mM | 48 h | growth inhibition=10﹪ | 25975637 | |
| T47D | Growth Inhibition Assay | 0.234 mM | 24 h | growth inhibition=10﹪ | 25975637 | |
| HeLa | Growth Inhibition Assay | 0.234 mM | 24 h | growth inhibition=5﹪ | 25975637 | |
| A549 | Growth Inhibition Assay | 0.234 mM | 24 h | growth inhibition=10﹪ | 25975637 | |
| Vero | Growth Inhibition Assay | 0.234 mM | 24 h | growth inhibition=5﹪ | 25975637 | |
| A549 | Function Assay | 1 μM | 48 h | increases AMPK phosphorylation and a concomitant decrease in AKT and mTOR phosphorylation cotreated with simvastatin | 26334320 | |
| MSTO-211H | Function Assay | 1 μM | 48 h | increases AMPK phosphorylation and a concomitant decrease in AKT and mTOR phosphorylation cotreated with simvastatin | 26334320 | |
| A549 | Apoptosis Assay | 1 μM | 24 h | induces apoptosis cotreated with simvastatin | 26334320 | |
| MSTO-211H | Apoptosis Assay | 1 μM | 24 h | induces apoptosis cotreated with simvastatin | 26334320 | |
| A549 | Function Assay | 1 μM | 24 h | enhances autophagy cotreated with simvastatin | 26334320 | |
| MSTO-211H | Function Assay | 1 μM | 24 h | enhances autophagy cotreated with simvastatin | 26334320 | |
| A549 | Cell Viability Assay | 1 μM | 48 h | enhances simvastatin inhibited viability | 26334320 | |
| MSTO-211H | Cell Viability Assay | 1 μM | 48 h | enhances simvastatin inhibited viability | 26334320 | |
| KB | Function assay | IC50 = 0.03 μM | 18680275 | |||
| RT16 | Antiproliferative assay | IC50 = 0.042 μM | 18680275 | |||
| D4 | Antiproliferative assay | IC50 = 0.06 μM | 18680275 | |||
| KB | Antiproliferative assay | IC50 = 0.068 μM | 18680275 | |||
| IGROV1 | Antiproliferative assay | IC50 = 0.102 μM | 18680275 | |||
| PC43-10 | Antiproliferative assay | IC50 = 0.138 μM | 18680275 | |||
| IGROV1 | Antiproliferative assay | IC50 = 0.2 μM | 18680275 | |||
| D4 | Antiproliferative assay | IC50 = 0.254 μM | 18680275 | |||
| KB | Antiproliferative assay | IC50 = 0.327 μM | 18680275 | |||
| RT16 | Antiproliferative assay | IC50 = 0.388 μM | 18680275 | |||
| R2 | Antiproliferative assay | IC50 = 0.894 μM | 18680275 | |||
| KB | Function assay | 30 mins | IC50 = 0.03 μM | 19371039 | ||
| R2 | Function assay | Ki = 0.096 μM | 20085328 | |||
| R2 | Function assay | Ki = 1.54 μM | 20085328 | |||
| KB | Function assay | IC50 = 30 μM | 20085328 | |||
| R2 | Antiproliferative assay | 10 to 14 days | IC50 = 0.00494 μM | 21879757 | ||
| R2 | Antiproliferative assay | 96 hrs | IC50 = 0.0132 μM | 21879757 | ||
| RT16 | Antiproliferative assay | 96 hrs | IC50 = 0.042 μM | 21879757 | ||
| D4 | Antiproliferative assay | 96 hrs | IC50 = 0.06 μM | 21879757 | ||
| KB | Antiproliferative assay | 96 hrs | IC50 = 0.068 μM | 21879757 | ||
| IGROV1 | Antiproliferative assay | 96 hrs | IC50 = 0.102 μM | 21879757 | ||
| PC43-10 | Antiproliferative assay | 96 hrs | IC50 = 0.138 μM | 21879757 | ||
| IGROV1 | Antiproliferative assay | 96 hrs | IC50 = 0.2 μM | 21879757 | ||
| D4 | Antiproliferative assay | 96 hrs | IC50 = 0.254 μM | 21879757 | ||
| KB | Antiproliferative assay | 96 hrs | IC50 = 0.327 μM | 21879757 | ||
| RT16 | Antiproliferative assay | 96 hrs | IC50 = 0.388 μM | 21879757 | ||
| R2 | Antiproliferative assay | 96 hrs | IC50 = 0.894 μM | 21879757 | ||
| R2(VC) | Antiproliferative assay | 96 hrs | IC50 = 0.974 μM | 21879757 | ||
| R2 | Function assay | Ki = 0.094 μM | 22243528 | |||
| R2 | Function assay | Ki = 2.54 μM | 22243528 | |||
| R2 | Growth inhibition assay | 96 hrs | IC50 = 0.0132 μM | 24111942 | ||
| RT16 | Growth inhibition assay | 96 hrs | IC50 = 0.042 μM | 24111942 | ||
| D4 | Growth inhibition assay | 96 hrs | IC50 = 0.06 μM | 24111942 | ||
| KB | Growth inhibition assay | 96 hrs | IC50 = 0.068 μM | 24111942 | ||
| PC43-10 | Growth inhibition assay | 96 hrs | IC50 = 0.138 μM | 24111942 | ||
| D4 | Growth inhibition assay | 96 hrs | IC50 = 0.254 μM | 24111942 | ||
| KB | Growth inhibition assay | 96 hrs | IC50 = 0.327 μM | 24111942 | ||
| RT16 | Growth inhibition assay | 96 hrs | IC50 = 0.388 μM | 24111942 | ||
| MTXRII-OuaR2-4 | Growth inhibition assay | 96 hrs | IC50 = 0.894 μM | 24111942 | ||
| R2(VC) | Growth inhibition assay | 96 hrs | IC50 = 0.974 μM | 24111942 | ||
| KB | Cytotoxicity assay | 96 hrs | IC50 = 0.00994 μM | 24256410 | ||
| KB | Function assay | 30 mins | IC50 = 0.01174 μM | 24256410 | ||
| RT16 | Cytotoxicity assay | 96 hrs | IC50 = 0.0182 μM | 24256410 | ||
| R2 | Cytotoxicity assay | 96 hrs | IC50 = 0.0223 μM | 24256410 | ||
| PC43-10 | Cytotoxicity assay | 96 hrs | IC50 = 0.0306 μM | 24256410 | ||
| KB | Cytotoxicity assay | 96 hrs | IC50 = 0.69 μM | 24256410 | ||
| R2/PCFT4 | Function assay | 96 hrs | IC50 = 0.0132 μM | 25234128 | ||
| RT16 | Function assay | 96 hrs | IC50 = 0.042 μM | 25234128 | ||
| D4 | Function assay | 96 hrs | IC50 = 0.06 μM | 25234128 | ||
| KB | Cytotoxicity assay | 96 hrs | IC50 = 0.068 μM | 25234128 | ||
| PC43-10 | Function assay | 96 hrs | IC50 = 0.138 μM | 25234128 | ||
| D4 | Function assay | 96 hrs | IC50 = 0.254 μM | 25234128 | ||
| KB | Cytotoxicity assay | 96 hrs | IC50 = 0.327 μM | 25234128 | ||
| RT16 | Function assay | 96 hrs | IC50 = 0.388 μM | 25234128 | ||
| R2 | Cytotoxicity assay | 96 hrs | IC50 = 0.894 μM | 25234128 | ||
| R2 | Cytotoxicity assay | 96 hrs | IC50 = 0.974 μM | 25234128 | ||
| KB | Function assay | 1 hr | IC50 = 0.01174 μM | 25602637 | ||
| R2/PCFT4 | Function assay | 96 hrs | IC50 = 0.0132 μM | 25602637 | ||
| RT16 | Function assay | 96 hrs | IC50 = 0.042 μM | 25602637 | ||
| R2 | Cytotoxicity assay | 96 hrs | IC50 = 0.042 μM | 25602637 | ||
| KB | Antiproliferative assay | 96 hrs | IC50 = 0.068 μM | 25602637 | ||
| PC43-10 | Function assay | 96 hrs | IC50 = 0.138 μM | 25602637 | ||
| R2(VC) | Cytotoxicity assay | 96 hrs | IC50 = 0.974 μM | 25602637 | ||
| KB | Cytotoxicity assay | 72 hrs | IC50 = 0.07 μM | 25668494 | ||
| A549 | Cytotoxicity assay | 72 hrs | IC50 = 0.08 μM | 25668494 | ||
| HepG2 | Cytotoxicity assay | 72 hrs | IC50 = 1.26 μM | 25668494 | ||
| R2/PCFT4 | Function assay | 2 mins | K = 0.044 μM | 26317331 | ||
| R2/PCFT4 | Function assay | 2 mins | K = 0.27 μM | 26317331 | ||
| KB | Antiproliferative assay | 72 hrs | IC50 = 0.07 μM | 27017552 | ||
| SW620 | Antiproliferative assay | 72 hrs | IC50 = 0.08 μM | 27017552 | ||
| A549 | Antiproliferative assay | 72 hrs | IC50 = 1.26 μM | 27017552 | ||
| KB | Function assay | 72 hrs | IC50 = 0.07 μM | 28830032 | ||
| SW620 | Antiproliferative assay | 72 hrs | IC50 = 0.09 μM | 28830032 | ||
| MCF7 | Antiproliferative assay | 72 hrs | IC50 = 0.65 μM | 28830032 | ||
| R2/PCFT4 | Function assay | 96 hrs | IC50 = 0.0132 μM | 29425443 | ||
| RT16 | Function assay | 96 hrs | IC50 = 0.042 μM | 29425443 | ||
| D4 | Function assay | 96 hrs | IC50 = 0.06 μM | 29425443 | ||
| KB | Antiproliferative assay | 96 hrs | IC50 = 0.068 μM | 29425443 | ||
| PC43-10 | Function assay | 96 hrs | IC50 = 0.138 μM | 29425443 | ||
| D4 | Function assay | 96 hrs | IC50 = 0.254 μM | 29425443 | ||
| R2/PCFT4 | Function assay | 2 mins | Ki = 0.259 μM | 29425443 | ||
| KB | Antiproliferative assay | 96 hrs | IC50 = 0.327 μM | 29425443 | ||
| R2 | Cytotoxicity assay | 96 hrs | IC50 = 0.849 μM | 29425443 | ||
| RT16 | Function assay | 96 hrs | IC50 = 0.894 μM | 29425443 | ||
| R2(VC) | Growth inhibition assay | 96 hrs | IC50 = 0.974 μM | 29425443 | ||
| A549 | Antiproliferative assay | 24 hrs | IC50 = 3.31 μM | 29807332 | ||
| MDA-MB-231 | Antiproliferative assay | 24 hrs | IC50 = 3.85 μM | 29807332 | ||
| OVCAR3 | Antiproliferative assay | 24 hrs | IC50 = 6.9 μM | 29807332 | ||
| SGC7901 | Antiproliferative assay | 24 hrs | IC50 = 9.08 μM | 29807332 | ||
| KB | Function assay | 1 uM | 24 hrs | Induction of apoptotic activity in human KB cells at 1 uM after 24 hrs | 18680275 | |
| R2 | Antiproliferative assay | Antiproliferative activity against chinese hamster R2 cells expressing human PCFT assessed as growth inhibition in the presence of 10 uM thymidine and 320 uM AICA | 21879757 | |||
| R2 | Antiproliferative assay | Antiproliferative activity against chinese hamster R2 cells expressing human PCFT assessed as growth inhibition in the presence of 60 uM adenosine | 21879757 | |||
| R2 | Function assay | Inhibition of GARFTase in chinese hamster R2 cells expressing human PCFT assessed as incorporation of [14C]glycine into [14C]formyl GAR in the presence of 4 uM azaserine | 21879757 | |||
| R2 | Function assay | 10 uM | Inhibition of human PCFT-mediated [3H]MTX uptake ectopically expressed in chinese hamster R2 cells at 10 uM at pH 5.5 to 7.2 | 21879757 | ||
| PC43-10 | Function assay | 10 uM | 2 mins | Inhibition of human RFC-mediated [3H]MTX uptake in chinese hamster PC43-10 cells at 10 uM after 2 mins relative to control | 21879757 | |
| KB | Function assay | 1 uM | 48 hrs | Inhibition of AICARFTase in human KB cells assessed as phosphorylated AMPK at 1 uM after 48 hrs by Western blot analysis | 24256410 | |
| KB | Cytotoxicity assay | 96 hrs | Cytotoxicity against human KB cells expressing human RFC/FRalpha/PCFT after 96 hrs by CellTitre-Blue fluorescence assay in presence of adenosine/AICA/thymidine | 24256410 | ||
| KB | Cell cycle arrest assay | 1 uM | 48 hrs | Cell cycle arrest in human KB cells assessed as accumulation at G1/G0 phase at 1 uM after 48 hrs by propidium iodide staining-based flow cytometry relative to control | 24256410 | |
| KB | Function assay | 48 hrs | Inhibition of AICARFTase in human KB cells assessed as accumulation of ZMP after 48 hrs by HPLC analysis | 24256410 | ||
| R2/PCFT4 | Function assay | 0.5 uM | 5 mins | Binding affinity to human PCFT expressed in Chinese hamster R2/PCFT4 cells assessed as intracellular drug level at 0.5 uM at 37 degC at pH 5.5 measured over 5 mins | 26317331 | |
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 29435139 | |||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) | 29435139 | |||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | |||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | |||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells | 29435139 | |||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells | 29435139 | |||
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells | 29435139 | |||
| IGROV1 | Function assay | Effect on TS protein expression in human IGROV1 cells by Western blot analysis | 30035541 | |||
| IGROV1 | Function assay | Effect on DHFR protein expression in human IGROV1 cells by Western blot analysis | 30035541 | |||
| IGROV1 | Function assay | Effect on HSP90 protein expression in human IGROV1 cells by Western blot analysis | 30035541 | |||
| Cliquez pour voir plus de données expérimentales sur la lignée cellulaire | ||||||
| Poids moléculaire | 471.37 | Formule | C20H19N5Na2O6 |
Stockage (À compter de la date de réception) | |
|---|---|---|---|---|---|
| N° CAS | 150399-23-8 | Télécharger le SDF | Stockage des solutions mères |
|
|
| Synonymes | LY-231514 disodium | Smiles | C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)[O-])C(=O)[O-].[Na+].[Na+] | ||
|
In vitro |
Water : 94 mg/mL
DMSO
: Insoluble
Ethanol : Insoluble |
|
In vivo |
|||||
Étape 1 : Saisir les informations ci-dessous (Recommandé : Un animal supplémentaire pour tenir compte des pertes pendant lexpérience)
Étape 2 : Saisir la formulation in vivo (Ceci est seulement le calculateur, pas la formulation. Veuillez nous contacter dabord sil ny a pas de formulation in vivo dans la section Solubilité.)
Résultats du calcul :
Concentration de travail : mg/ml;
Méthode de préparation du liquide maître DMSO : mg médicament prédissous dans μL DMSO ( Concentration du liquide maître mg/mL, Veuillez nous contacter dabord si la concentration dépasse la solubilité du DMSO du lot de médicament. )
Méthode de préparation de la formulation in vivo : Prendre μL DMSO liquide maître, puis ajouterμL PEG300, mélanger et clarifier, puis ajouterμL Tween 80, mélanger et clarifier, puis ajouter μL ddH2O, mélanger et clarifier.
Méthode de préparation de la formulation in vivo : Prendre μL DMSO liquide maître, puis ajouter μL Huile de maïs, mélanger et clarifier.
Note : 1. Veuillez vous assurer que le liquide est clair avant dajouter le solvant suivant.
2. Assurez-vous dajouter le(s) solvant(s) dans lordre. Vous devez vous assurer que la solution obtenue, lors de lajout précédent, est une solution claire avant de procéder à lajout du solvant suivant. Des méthodes physiques telles que le vortex, les ultrasons ou le bain-marie chaud peuvent être utilisées pour faciliter la dissolution.
| Targets/IC50/Ki |
TS
(Cell-free assay) 1.3 nM(Ki)
DHFR
(Cell-free assay) 7.2 nM(Ki)
GARFT
(Cell-free assay) 65 nM(Ki)
|
|---|---|
| In vitro |
Pemetrexed disodium montre une activité antiproliférative dans les cellules de leucémie CCRF-CEM, de carcinome du côlon GC3/C1 et de carcinome iléocœcal HCT-8 avec des IC50 de 25 nM, 34 nM et 220 nM, respectivement. Une étude récente montre que le cisplatine plus ce composé, combiné à l'administration du gène SOCS-1, présente un effet antitumoral par inhibition de la prolifération cellulaire, de l'invasivité et induction de l'apoptose dans les cellules de MPM infectées par un vecteur adénoviral exprimant SOCS-1.
|
| Essai kinase |
Tests enzymatiques et méthodes.
|
|
L'activité de la TS est mesurée à l'aide d'une méthode spectrophotométrique, qui implique le suivi de l'augmentation de l'absorbance à 340 nm résultant de la formation du produit, le 7,8-dihydrofolate. Le tampon d'essai contient 50 mM d'acide N-tris[hydroxyméthyljméthyl-2-aminoéthanesulfonique, 25 mM de MgC12, 6,5 mM de formaldéhyde, 1 mM d'EDTA et 75 mM de 2-mercaptoéthanol, pH 7,4. Les concentrations de désoxyuridylate monophosphate, de 6R-MTHF et de hIS sont de 100 μM, 30 μM et 30 nM (1,7 milliunité/mL), respectivement. À la concentration de 6R-MTHF, une réaction non inhibée et six concentrations d'inhibiteur sont testées. Les valeurs de Ki app sont déterminées en ajustant les données à l'équation de Morrison à l'aide d'une analyse de régression non linéaire avec l'aide du programme ENZFITTER. Les valeurs de Ki sont calculées à l'aide de l'équation : Ki app= Ki(1 + [S]/Km), où [S] est égal à 30 μM et Km est égal à 3 μM. L'activité de la DHFR est mesurée spectrophotométriquement en suivant la disparition des substrats NADPH et 7,8-dihydrofolate à 340 nm. La réaction a lieu à 25°C dans 0,5 mL de tampon phosphate de potassium 50 mM, qui contient 150 mM de KC1 et 10 nM de 2-mercaptoéthanol, pH 7,5, et 14 nM (0,34 milliunité/mL) de DHFR. La concentration de NADPH est de 10 μM et le 7,8-dihydrofolate est varié à 5, 10 ou 15 μM. À chaque concentration de 7,8-dihydrofolate, une réaction non inhibée et sept concentrations d'inhibiteur sont testées. Le programme micro-informatique ENZFITI'ER est utilisé pour obtenir les valeurs de Ki app en ajustant les données à l'équation de Morrison par analyse de régression non linéaire. Ki app= Ki(1 + [S]/Km), où [S] est égal à la concentration de 7,8-dihydrofolate utilisée et Km du 7,8-dihydrofolate est égal à 0,15 μM. L'activité de la GARFT est mesurée spectrophotométriquement en suivant l'augmentation de l'absorbance résultant de la formation du produit 5,8-didéazafolate à 295 nm. Le solvant de réaction contient 75 mM de HEPES, 20 % de glycérol et 50 mM d'a-thioglycérol, pH 7,5, à 25°C. Les concentrations de substrats et d'enzyme utilisées sont 10 μM d'α,β-glycinamide ribonucléotide, 0-10 μM d'acide 10-formyl-5,8-didéazafolique et 10 nM (1,9 milliunité/mL) de GARFT. Les valeurs de Ki sont calculées à l'aide du programme Enzyme Mechanism du spectrophotomètre Beckman DU640, qui utilise une analyse de régression non linéaire pour ajuster les données à l'équation de Michaelis-Menten pour l'inhibition compétitive.
|
|
| In vivo |
Chez la souris xénogreffée de carcinome pulmonaire non à petites cellules H460 humain, le Pemetrexed disodium produit un retard de croissance tumorale (TGD) dépendant de la durée.
|
Références |
|
| Méthodes | Biomarqueurs | Images | PMID |
|---|---|---|---|
| Western blot | EGFR / p-EGFR AKT / p-AKT / GSK3β / p-GSK3β Topo IIα / Topo I / γH2AX / Cleaved PARP / Survivin p-Chk1 / Chk1 / Cyclin D / Cyclin E / p-Histone H3 / Histone H3 / Cyclin B1 / p-Cdc2 / Cdc2 |
|
30953548 |
| Immunofluorescence | p-AKT |
|
24847863 |
| Growth inhibition assay | Cell viability |
|
28719077 |
(données du https://clinicaltrials.gov, mis à jour le 2024-05-22)
| Numéro NCT | Recrutement | Conditions | Promoteur/Collaborateurs | Date de début | Phases |
|---|---|---|---|---|---|
| NCT06378892 | Recruiting | Non Small Cell Lung Cancer Metastatic|ALK Gene Mutation |
Centro di Riferimento Oncologico - Aviano |
March 15 2024 | Phase 2 |
| NCT06010277 | Recruiting | NSCLC|Mesothelioma|Thymoma |
Amphia Hospital|Albert Schweitzer Hospital |
February 6 2023 | Phase 4 |
Tel: +1-832-582-8158 Ext:3
Si vous avez dautres questions, veuillez laisser un message.